DALY SEES 'NO URGENCY TO ADJUST THE POLICY RATE'

MNI BRIEF: Fed’s Collins Sees Rate Cuts Later Than Had Thought

MNI BRIEF: China March M2 Slows More Than Expected

MNI BRIEF: China Tightens Stock Market Supervision

MNI BRIEF: China Mar Exports Jump On Demand; Imports Improve

MNI: PBOC Sets Yuan Parity Lower At 7.0967 Fri; -4.87% Y/Y

MNI: BAKER HUGHES US RIG COUNT 617; OIL RIGS 506; GAS RIGS 109

March Home Sales Jumped At End Of Month

MNI BRIEF: Poilievre Calls QE 'Scam' And Would Limit BOC Remit

MNI: Growth Drag From Net Zero Carbon Goal Can Be Offset-OECD

MNI BRIEF: Lawmakers Signal Tough Hearing For BOC's Macklem

© 1982-2023 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

China May Soon Allow BioNTech Vaccine: Newspaper

CHINA PRESS
MNI (Singapore)

China has reached "final stage" in approving the use of BioNTech's mRNA COVID-19 vaccine in cooption with Shanghai-based Fosun Pharma, the Global Times reported citing an interview with the German company's CEO Ugur Şahin. The developer is evaluating combining mRNA vaccines with inactivated and adenovirus vector jabs as booster shots to stabilize antibody levels against the coronavirus, Sahin was cited as saying. BioNTech is expected to be the first foreign-developed COVID-19 vaccine that China will import to pave the way for mixed shots in sequential inoculation, the newspaper said citing Shao Yiming, leading physician-scientist and immunologist serving at the Chinese Center for Disease Control and Prevention.

Energy BulletsCommodities
Energy BulletsCommodities

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.